Eiger Biopharmaceuticals Inc buy Quitte
Start price
17.01.18
/
50%
€7.71
Target price
17.07.18
€14.25
Performance (%)
29.24%
End price
17.07.18
€9.97
Summary
This prediction ended on 17.07.18 with a price of €9.97. The prediction had a final performance of 29.24%. Quitte has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Eiger Biopharmaceuticals Inc | - | - | - | - |
| iShares Core DAX® | -1.553% | -0.123% | 12.654% | 57.846% |
| iShares Nasdaq 100 | -0.386% | -0.595% | 4.546% | 93.736% |
| iShares Nikkei 225® | 1.640% | 5.468% | 17.939% | 51.788% |
| iShares S&P 500 | 0.114% | -0.217% | 1.586% | 61.648% |
Comments by Quitte for this prediction
In the thread Eiger Biopharmaceuticals Inc diskutieren
Ubenimex -Abbruch vermutlich kein Beinbruch
denn:
Zur Eiger-Pipeline gehören auch die für Hepatitis Delta entwickelten Lonafarnib- und Pegylated Interferon Lambda-Sonden. Beide Kandidaten befinden sich derzeit in Phase 2. HDV ist die schwerste Form der Virushepatitis und betrifft schätzungsweise 15-20 Millionen Menschen weltweit.
Quelle: Seeking Alpha
(Laufzeit überschritten)
Stopped prediction by Quitte for Eiger Biopharmaceuticals Inc
Eiger Biopharmaceuticals Inc
Start price
Target price
Perf. (%)
€12.04
03.09.18
03.09.18
€14.03
04.11.21
04.11.21
-43.65%
05.11.21
05.11.21
Eiger Biopharmaceuticals Inc
Start price
Target price
Perf. (%)
€6.37
21.06.17
21.06.17
€9.92
24.10.17
24.10.17
55.71%
24.10.17
24.10.17
Eiger Biopharmaceuticals Inc
Start price
Target price
Perf. (%)
€15.80
19.11.15
19.11.15
€18.75
31.03.16
31.03.16
-6.89%
31.03.16
31.03.16
Eiger Biopharmaceuticals Inc
Start price
Target price
Perf. (%)
€17.99
16.09.15
16.09.15
€24.22
10.11.15
10.11.15
-21.80%
10.11.15
10.11.15
Eiger Biopharmaceuticals Inc
Start price
Target price
Perf. (%)
€36.77
28.04.15
28.04.15
€43.50
29.06.15
29.06.15
-54.02%
29.06.15
29.06.15